Infliximab in inflammatory bowel disease: attention to adverse events

Basit Öğe Kaydı
dc.contributor.authorUyanıkoğlu, Ahmet
dc.contributor.authorErmiş, Fatih
dc.contributor.authorAkyüz, Filiz
dc.contributor.authorPınarbaşı, Binnur
dc.contributor.authorBaran, Bülent
dc.contributor.authorAydoğan, Timuçin
dc.contributor.authorKaymakoğlu, Sabahattin
dc.date.accessioned2020-04-30T23:18:30Z
dc.date.available2020-04-30T23:18:30Z
dc.date.issued2014
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionUyanikoglu, Ahmet/0000-0003-4881-5244; Baran, Bulent/0000-0001-7966-2346;en_US
dc.descriptionWOS: 000352203200017en_US
dc.descriptionPubMed: 25219835en_US
dc.description.abstractOBJECTIVE: To assess the efficacy and adverse effects of infliximab in patients with Crohn's disease and ulcerative colitis who are resistant to conventional therapy or having fistulising type Crohn's disease. PATIENTS AND METHODS: The patients with a diagnosis of inflammatory bowel disease received infliximab between 2007 and 2009 were followed-up prospectively. Infliximab 5 mg/kg was given at week 0, 2, 6, and every 8 weeks thereafter. Early and late adverse events occurring during the treatment were recorded for each patient. RESULTS: There were 36 patients [mean age 35 +/- 12, 17 male] included in the study. Thirty-two (88%) patients were receiving concomitant long-term immunosuppressive therapy. Complete or partial response was obtained in 75% of all patients. At least one adverse event was observed in 10 (28%) patients. Anaphylaxis was seen in 2 (6%) patients, mild acute infusion reaction in 2 (6%) patients, hypotension in 2 (6%) patients, respiratory distress in 2 (6%) patients, skin rash and eruptions in 2 (6%) patients, one hypertension (3%) and one (3%) tightness in the chest. Treatment was continued in all except patients with anaphylaxis. No infection, tumour or cases of death were observed. CONCLUSIONS: Several adverse events might be observed in patients who receive infliximab. Care should be given to patients whom treatment was restarted after a break in regard to anaphylaxis. No serious adverse event was observed during infliximab treatment except allergic events.en_US
dc.identifier.endpage2342en_US
dc.identifier.issn1128-3602
dc.identifier.issue16en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2337en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3356
dc.identifier.volume18en_US
dc.identifier.wosWOS:000352203200017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical And Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInfliximaben_US
dc.subjectInflammatory bowel diseaseen_US
dc.subjectTreatmenten_US
dc.subjectAdverse eventen_US
dc.titleInfliximab in inflammatory bowel disease: attention to adverse eventsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
3356.pdf
Boyut:
125.62 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu